Can GLP-1 Medications Help With Sleep Apnea?

What Is Obstructive Sleep Apnea?

Obstructive sleep apnea (OSA) is a condition in which the upper airway repeatedly collapses during sleep, causing brief pauses in breathing that may occur dozens or even hundreds of times per night. Each episode briefly rouses the brain, fragmenting sleep without the person fully waking. The result is poor sleep quality, chronic fatigue, and intermittent drops in blood-oxygen levels that place ongoing stress on the heart and blood vessels.

Sleep specialists measure OSA severity using the apnea-hypopnea index (AHI) — the average number of breathing-pause events per hour of sleep. An AHI of 5 to 14 is mild; 15 to 29 is moderate; 30 or more is severe. Values below 5 fall within the normal range.

Roughly 30 million Americans are estimated to have OSA, yet most cases remain undiagnosed. Untreated moderate-to-severe OSA is associated with elevated risk of high blood pressure, heart disease, stroke, and type 2 diabetes.

How Excess Weight Worsens Sleep Apnea

Obesity is the strongest modifiable risk factor for obstructive sleep apnea. Fat deposits around the neck, throat, and tongue physically narrow the upper airway. When muscles naturally relax during sleep, that already-narrowed passage becomes more susceptible to collapse. Abdominal fat also presses upward on the diaphragm, reducing lung volume and weakening the mechanical tension that helps keep the airway stable through the night.

The relationship is proportional: higher body weight generally correlates with more severe OSA, and meaningful weight loss — whether through lifestyle changes, bariatric surgery, or medication — has long been documented to reduce AHI. This biological link is the foundation on which GLP-1 receptor agonists emerged as a plausible treatment for OSA.

The Landmark FDA Approval: Zepbound for Sleep Apnea

In December 2024, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) as the first medication with a specific indication for moderate-to-severe obstructive sleep apnea in adults with obesity. For the first time, a pharmacologic treatment was recognized not merely for weight management but for OSA itself.

The approval was based on two randomized, placebo-controlled Phase 3 studies — collectively the SURMOUNT-OSA trials — published in The New England Journal of Medicine in 2024. One trial enrolled adults with moderate-to-severe OSA not using PAP therapy; the second enrolled adults on PAP therapy who agreed to pause it for the study period.

What the SURMOUNT-OSA Trials Found

Across both trials, participants treated with tirzepatide experienced substantial, clinically meaningful reductions in AHI compared with placebo, and the difference between groups was large. A meaningful proportion of participants in the tirzepatide arm achieved AHI levels consistent with mild disease or below — a threshold investigators described as disease resolution.

Secondary outcomes also favored tirzepatide: improvements in hypoxic burden, patient-reported sleepiness, blood pressure, and waist circumference. Participants lost a significant percentage of body weight, and OSA improvements tracked closely with the degree of weight loss, pointing to weight reduction as the primary driver of benefit.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates two complementary pathways, producing substantial and sustained weight loss which in turn reduced the anatomical burden on the upper airway during sleep.

Why GLP-1 Medications Improve Sleep Apnea

The predominant mechanism is weight loss-driven reduction of pharyngeal fat. As excess adipose tissue around the neck, tongue base, and lateral pharyngeal walls decreases, the airway widens and becomes less prone to collapse during sleep. Abdominal weight loss also improves diaphragmatic movement, supporting respiratory mechanics through the night.

Researchers continue to examine whether GLP-1 receptors in brainstem regions governing respiratory rhythm might contribute additional benefit, but SURMOUNT-OSA data firmly identify weight loss as the dominant mechanism. In practice, benefit accumulates gradually over months — not overnight the way CPAP does — as the medication progressively reduces body weight.

GLP-1 Therapy and CPAP: Partners, Not Rivals

Continuous positive airway pressure (CPAP) remains the established first-line treatment for moderate-to-severe OSA, backed by decades of evidence for reducing cardiovascular risk, improving daytime function, and raising quality of life. A GLP-1 medication is not an automatic replacement for CPAP.

For many patients, the two approaches are complementary: GLP-1 therapy addresses the excess weight driving OSA over months, while CPAP provides reliable, immediate airway protection every night in the interim. Whether a person can safely reduce or discontinue CPAP is an individualized clinical decision — not one to make unilaterally — ideally confirmed by a follow-up sleep study measuring the new AHI.

• Do not stop CPAP without provider guidance. Even if you feel more rested, untreated moderate-to-severe OSA carries cardiovascular risk.
• A repeat sleep study after meaningful weight loss is the appropriate way to confirm AHI improvement before changing therapy.
• Some patients achieve sufficient reduction to step down CPAP; others continue to benefit from both treatments long-term.

Where Semaglutide Fits In

Semaglutide (Wegovy for chronic weight management; Ozempic for type 2 diabetes) does not carry an FDA-approved indication for obstructive sleep apnea. However, semaglutide produces substantial weight loss in adults with obesity, and weight loss reliably reduces OSA severity. Analyses from the STEP program and related research suggest semaglutide users experience AHI reductions proportional to their weight loss.

This is clinically meaningful for patients prescribed semaglutide for weight management who also have OSA — but it reflects a weight-loss benefit, not a labeled OSA treatment. Tirzepatide's dual GIP/GLP-1 mechanism typically produces greater average weight loss than semaglutide, which may translate to greater average OSA improvement, though individual responses vary.

A note on compounded medications: compounded tirzepatide and compounded semaglutide are not FDA-approved for any indication, including obstructive sleep apnea. They are not manufactured or evaluated to the same regulatory standards as branded products.

Who Might Be a Candidate — and What to Discuss With Your Provider

You may be a candidate for GLP-1 therapy with potential OSA benefit if you have:

• Confirmed moderate-to-severe OSA from a sleep study (home sleep test or in-lab polysomnography)
• Obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related health condition
• Difficulty tolerating CPAP, or interest in addressing the weight-related root cause of your OSA alongside CPAP
• No contraindications to GLP-1 therapy, such as personal or family history of medullary thyroid carcinoma or MEN2 syndrome

Questions worth raising with your provider:

• Am I a candidate for Zepbound specifically for the OSA indication, or is weight management the primary goal?
• Should I continue CPAP while starting GLP-1 therapy, and when should we formally reassess?
• What AHI result on a follow-up sleep study would change your recommendation about my CPAP therapy?
• What lifestyle changes would maximize my OSA improvement alongside this medication?

Realistic expectations: meaningful AHI reductions typically emerge over three to six months and continue accumulating over one to two years with sustained weight loss. GLP-1 therapy works best as part of a comprehensive plan that includes dietary guidance and regular physical activity.